FDA granted accelerated approval to Beqalzi (sonrotoclax), the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma in adults after at least two prior lines including a BTK inhibitor. The decision was supported by phase 1/2 BGB-11417-201 data, including an overall response rate of 52% and a complete response rate of 16%.